Chia Tai Enterprises International Limited (HK:3839)
:3839
Top Page
Chia Tai Enterprises International
(3839)
Select Model
Select Model
Rating:62Neutral
Price Target:
HK$7.50
▲(10.46% Upside)
Action:ReiteratedDate:11/30/25
The overall score of 62 for HK:3839 is driven primarily by mixed financial performance, with strong revenue growth offset by negative free cash flow and debt concerns. An attractive P/E ratio of 7.41 provides a positive valuation outlook, while neutral-to-bearish technical indicators limit upside potential in the short term.
Positive Factors
Revenue Growth
The company's strong revenue growth indicates expanding market reach and successful product adoption, which are critical for long-term business sustainability and competitive positioning.
Negative Factors
Cash Flow Challenges
The absence of positive cash flow suggests potential liquidity constraints, which could limit the company's ability to invest in growth and manage financial obligations effectively.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The company's strong revenue growth indicates expanding market reach and successful product adoption, which are critical for long-term business sustainability and competitive positioning.
Read all positive factors
Chia Tai Enterprises International (3839) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.73B
Dividend YieldN/A
Average Volume (3M)166.49K
Price to Earnings (P/E)7.3
Beta (1Y)1.51
Revenue Growth153.95%
EPS Growth551.46%
CountryHK
Employees900
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.26
Shares Outstanding240,718,300
10 Day Avg. Volume121,886
30 Day Avg. Volume166,494
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.21
Price to Sales (P/S)0.16
P/FCF Ratio-18.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Chia Tai Enterprises International Business Overview & Revenue Model
Company Description
Chia Tai Enterprises International Limited engages in the manufacture and sale of chlortetracycline (CTC) and other related products in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments, ...
How the Company Makes Money
Chia Tai Enterprises International generates revenue through multiple streams, primarily from the sale of seeds and agricultural products. The company leverages its extensive research and development initiatives to create high-quality seeds tailor...
Chia Tai Enterprises International Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
65
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 523.10M | 307.75M | 173.98M | 159.24M | 142.41M | 93.58M |
| Gross Profit | 72.73M | 48.93M | 30.18M | 39.19M | 34.76M | 24.90M |
| EBITDA | 39.46M | 17.51M | 11.29M | 5.17M | 12.38M | 23.73M |
| Net Income | 26.25M | 11.17M | 2.55M | -6.68M | 19.56M | 16.25M |
Balance Sheet | ||||||
| Total Assets | 448.53M | 422.21M | 377.37M | 350.58M | 365.22M | 330.70M |
| Cash, Cash Equivalents and Short-Term Investments | 35.49M | 32.38M | 37.61M | 30.86M | 31.09M | 32.26M |
| Total Debt | 59.09M | 69.17M | 78.17M | 49.10M | 42.61M | 20.50M |
| Total Liabilities | 163.63M | 161.70M | 125.36M | 94.83M | 81.69M | 80.09M |
| Stockholders Equity | 255.65M | 234.77M | 228.43M | 230.85M | 253.06M | 228.00M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.56M | -27.17M | -10.38M | -28.46M | -9.23M |
| Operating Cash Flow | 0.00 | 11.29M | -16.06M | 5.63M | -10.91M | 4.03M |
| Investing Cash Flow | 0.00 | -9.27M | -7.14M | -15.64M | -9.84M | -10.87M |
| Financing Cash Flow | 0.00 | -7.07M | 30.23M | 10.38M | 19.36M | 249.00K |
Chia Tai Enterprises International Technical Analysis
Positive
6.79
Price Trends
6.49
Positive
6.72
Positive
6.61
Positive
Market Momentum
0.14
Negative
55.36
Neutral
69.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3839, the sentiment is Positive. The current price of 6.79 is above the 20-day moving average (MA) of 6.54, above the 50-day MA of 6.49, and above the 200-day MA of 6.61, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 55.36 is Neutral, neither overbought nor oversold. The STOCH value of 69.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3839.
Chia Tai Enterprises International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$25.63B | 22.15 | 7.26% | 3.13% | 10.56% | -13.58% | |
71 Outperform | HK$20.80B | 9.66 | 12.63% | 5.11% | 0.39% | 4.94% | |
64 Neutral | HK$712.49M | 6.31 | 5.44% | 2.92% | 19.80% | 55.09% | |
62 Neutral | HK$1.73B | 7.35 | 12.24% | ― | 153.95% | 551.46% | |
54 Neutral | HK$9.06B | -28.37 | -1.64% | 3.66% | -9.58% | -128.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$416.29M | 43.63 | -1.17% | 7.50% | 59.60% | -351.02% |
* Healthcare Sector Average
HK:3839
Chia Tai Enterprises International
6.83
5.48
405.93%
HK:3933
The United Laboratories International Holdings
10.54
-0.25
-2.29%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.80
0.08
4.59%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.37
0.01
2.78%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.21
0.00
0.00%
HK:0512
Grand Pharmaceutical Group Limited
7.22
1.88
35.21%
Chia Tai Enterprises International Corporate Events
Chia Tai Enterprises Forecasts Profit Surge for 2025 Despite China Farming Slowdown
Jan 22, 2026
Chia Tai Enterprises International Limited has issued an inside information announcement indicating it expects a substantial rise in consolidated profit attributable to shareholders to about US$32 million for the year ended 31 December 2025, up fr...
Chia Tai Enterprises Updates Audit Committee Terms for Enhanced Governance
Nov 10, 2025
Chia Tai Enterprises International Limited has updated the terms of reference for its Audit Committee, originally established by the board of directors in 2014. The Committee, which consists solely of non-executive directors, is responsible for ov...
Chia Tai Enterprises Updates Remuneration Committee Terms
Nov 10, 2025
Chia Tai Enterprises International Limited has updated the terms of reference for its Remuneration Committee, which was initially established by the board of directors in 2014. The committee is responsible for developing a transparent remuneration...
Chia Tai Enterprises Updates Nomination Committee Terms
Nov 10, 2025
Chia Tai Enterprises International Limited has updated the terms of reference for its Nomination Committee, which was initially established in 2014. The committee’s responsibilities include formulating and implementing policies related to no...
Chia Tai Enterprises Reports Strong Nine-Month Financial Performance
Nov 10, 2025
Chia Tai Enterprises International Limited announced its unaudited consolidated results for the nine months ended September 30, 2025, reporting a significant increase in revenue and profit compared to the previous year. The company’s profit ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.